{
    "organizations": [],
    "uuid": "12618f8a9e2a866176e81b1ae46d191c8a034a19",
    "author": "",
    "url": "https://www.reuters.com/article/brief-endocyte-and-itm-announce-supply-a/brief-endocyte-and-itm-announce-supply-agreement-idUSASB0C7EO",
    "ord_in_thread": 0,
    "title": "BRIEF-Endocyte And ITM Announce Supply Agreement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 17 PM / Updated 6 minutes ago BRIEF-Endocyte And ITM Announce Supply Agreement Reuters Staff Feb 26 (Reuters) - Endocyte Inc: * ENDOCYTE AND ITM ANNOUNCE SUPPLY AGREEMENT FOR NO-CARRIER-ADDED LUTETIUM FOR THE PHASE 3 VISION TRIAL * ENDOCYTE INC - UNDER SUPPLY AGREEMENT, ITM TO SUPPLY TO CO, MEDICAL RADIOISOTOPE NO-CARRIER-ADDED LUTETIUM, ENDOLUCINBETA * ENDOCYTE INC - PHASE 3 VISION TRIAL EXPECTED TO BE INITIATED BY ENDOCYTE IN Q2 OF 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-02-26T15:16:00.000+02:00",
    "crawled": "2018-02-26T15:27:09.026+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "itm",
        "announce",
        "supply",
        "agreement",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "endocyte",
        "inc",
        "endocyte",
        "itm",
        "announce",
        "supply",
        "agreement",
        "lutetium",
        "phase",
        "vision",
        "trial",
        "endocyte",
        "inc",
        "supply",
        "agreement",
        "itm",
        "supply",
        "co",
        "medical",
        "radioisotope",
        "lutetium",
        "endolucinbeta",
        "endocyte",
        "inc",
        "phase",
        "vision",
        "trial",
        "expected",
        "initiated",
        "endocyte",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}